Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040183 · ClinicalTrials.gov registry record · Phase 3
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
A Phase 3 study of Pancreatic Cancer, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
- 20
- Study locations
NCT00040183 is a Phase 3 study of Pancreatic Cancer that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 569 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00040183, a Phase 3 study of Pancreatic Cancer, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
Conditions Studied
Interventions
- DRUG Tarceva (erlotinib HCl, OSI-774)
Study Locations (20)
California
- Alta Bates Comprehensive Cancer Center - Berkeley
- Loma Linda University Cancer Institute - Loma Linda
- Metropolitan Hematology/Oncology Medical Group, Inc. - Los Angeles
- UCLA Medical Center - Los Angeles
- Kaiser Permanente - San Diego
Connecticut
- DeQuattro Community Cancer Center - Manchester
- New Britain General Hospital - New Britain
- Eastern Connecticut Oncology - Norwich
- Carl and Dorothy Bennett Cancer Center - Stamford
Florida
- Florida Cancer Specialists - Fort Myers
- Oncology Hematology Group of South Florida - Miami
- Ocala Oncology - Ocala
- Tampa General Hospital - Tampa
Illinois
- Onc/Hem Associates of Central Illinois - Peoria
- Hematology Oncology Associates of Illinois - Skokie
- Carle Cancer Center - Urbana
Arizona
- Arizona Clinical Research Center - Tucson
Arkansas
- Highlands Oncology Group - Springdale
Georgia
- Atlanta Cancer Center - Atlanta
Iowa
- University of Iowa Hospital & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2001-11-29 |
| Est. Completion | 2004-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040183
The ClinicalTrials.gov registry entry for NCT00040183 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 569 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (46% higher). The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarceva (erlotinib HCl, OSI-774) is the first listed.
NCT00040183 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00040183 about?
NCT00040183 is a clinical study titled "OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.". The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
What is the current status of trial NCT00040183?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2001-11-29. Estimated completion is 2004-01-15.
What conditions does trial NCT00040183 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00040183?
The interventions under investigation include: Tarceva (erlotinib HCl, OSI-774) (DRUG).
Who is sponsoring clinical trial NCT00040183?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00040183 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.